National Action Plan for Adverse Drug Event (ADE) Prevention
Adverse drug events (ADEs) have been defined as an injury resulting from medical intervention related to a drug. ADEs can occur in any health care setting, including inpatient (for example, acute care hospitals), outpatient, and long-term care settings (for example, nursing homes). Given the U.S. population’s large and ever-increasing magnitude of medication exposure, the potential for harms from ADEs constitutes a critical patient safety and public health challenge.
- Inpatient settings: ADEs comprise an estimated one-third of all hospital adverse events, affect approximately two million hospital stays annually, and prolong hospital length of stay by approximately 1.7 to 4.6 days.
- Outpatient settings: ADEs account for over 3.5 million physician office visits, an estimated one million emergency department visits, and approximately 125,000 hospital admissions each year.
Draft National Action Plan for ADE Prevention
The draft National Action Plan for Adverse Drug Event (ADE) Prevention seeks to engage all stakeholders in coordinated, aligned, multi‐sector, and health literate effort to reduce ADEs that are the most common, clinically significant, preventable, and measurable. The draft National Action Plan for ADE Prevention has two key objectives:
- Identify common, clinically significant, preventable, and measurable ADEs.
- Align the efforts of federal health agencies to reduce patient harms from these specific ADEs nationally.
Based on national ADE data from inpatient and outpatient settings, three types of ADEs were considered to be common, clinically significant, preventable, and measureable, and therefore selected as the high-priority targets of this Action Plan: anticoagulants, diabetes agents, and opioids.
The draft Action Plan suggests a four-pronged approach to reduce patient harms from these three ADEs: Surveillance, Prevention, Incentives and Oversight, and Research. The draft Action Plan identifies the federal government’s highest priority strategies and opportunities for advancement that will have the greatest impact on reducing ADEs. The implementation of these strategies is expected to result in safer and higher quality health care services, reduced health care costs, informed and engaged consumers, and, ultimately, improved health outcomes.
The draft Action Plan provides federal agencies and external stakeholders with a framework to identify strategies and select specific actions to take. The intended end‐users of the draft Action Plan are policymakers, health care professionals, public and private sector organizations, and communities who can organize and take action towards preventing high‐priority ADEs. The draft Action Plan should serve as a catalyst to promote leaders at the federal, state, and local levels to implement evidence-based guidelines and engage in strategies that will help to advance the goals of the draft Action Plan.
Draft National Action Plan for Adverse Drug Event (ADE) Prevention [PDF – 2MB]
The Office of Disease Prevention and Health Promotion (ODPHP), on behalf of the Health and Human Services (HHS) Steering Committee for Adverse Drug Event Prevention, is soliciting public comment on the DRAFT National Action Plan for Adverse Drug Event Prevention.
Comments on the draft National Action Plan for Adverse Drug Event Prevention must be received no later than 5 p.m. on October 4, 2013.
Comments are preferred electronically and may be addressed to ADE@hhs.gov. Please use the title “Draft National ADE Action Plan” when sending comments electronically.
Written responses should be addressed to the Department of Health and Human Services, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, Suite LL100, Rockville MD 20852, Attention: Draft National ADE Action Plan.